


# Major R&D Pipeline: 3ADCs

As of July 2021

	Phase 1	Phase 2	Phase 3	Submitted
(JP/US) NSCLC, TNBC, HR+ BC TROPION-PanTumor01	(US/EU/Asia) HER2+ BC 2L~/1L DESTINY-Breast07	(US/EU/Asia) TNBC (durvalumab combo) BEGONIA	(JP/US/EU/Asia)HER2+ BC 3L DESTINY-Breast02	
(JP/US/EU/Asia) NSCLC (w/o actionable mutation, pembrolizumab combo) TROPION-Lung02	(US/EU/Asia) HER2 low BC chemo naïve/ post chemo DESTINY-Breast08	(US/EU) HER2+ GC 2L DESTINY-Gastric02	(JP/US/EU/Asia) HER2+ BC 2L DESTINY-Breast03	
(JP/US/EU/Asia) NSCLC (w/o actionable mutation, durvalumab combo) TROPION-Lung04	(US/EU/Asia) HER2+ GC combo, 2L~/1L DESTINY-Gastric03	(JP/US/EU)HER2+/mutated NSCLC 2L~ DESTINY-Lung01	(JP/US/EU/Asia) HER2 low BC post chemo DESTINY-Breast04	
(US/EU/Asia) TNBC (durvalumab combo) BEGONIA	(EU/Asia)HER2+ NSCLC (durvalumab combo) 1L DESTINY-Lung03	(JP/US/EU/Asia) HER2 mutated NSCLC 2L~ DESTINY-Lung02	(JP/US/EU/Asia) HER2+ BC post neoadjuvant DESTINY-Breast05	
(JP/US/EU/Asia) NSCLC	(US/EU) BC, bladder (nivolumab combo)	(US/EU/Asia) NSCLC (durvalumab combo) 2L~ HUDSON	(JP/US/EU/Asia) HER2 low BC chemo naïve DESTINY-Breast06	
(JP/US)EGFR mutated NSCLC (osimertinib combo)	(US/EU) BC, NSCLC (pembrolizumab combo)	(JP/US/EU) HER2+ CRC 3L DESTINY-CRC01	(US)HER2+ BC 1L DESTINY-Breast09	
(JP/US) BC		(JP/US/EU/Asia) HER2+ CRC 3L DESTINY-CRC02	(JP/EU/Asia) HER2+ GC 2L DESTINY-Gastric04	
		(US/EU/Asia) HER2 mutated tumor DESTINY-PanTumor01	(JP/US/EU/Asia) NSCLC (w/o actionable mutation) TROPION-Lung01	
		(US/EU/Asia) HER2 expressing tumor DESTINY-PanTumor02		
		(JP/US/EU/Asia) NSCLC (w/ actionable mutation) TROPION-Lung05		
		(JP/US/EU/Asia) EGFR mutated NSCLC HERTHENA-Lung01		
		(JP/US/EU) CRC 3L		










- T-DXd
- Dato-DXd
- HER3-DXd

BC: breast cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, TNBC: triple negative breast cancer  
 : project in oncology that is planned to be submitted for approval based on the results of phase 2 trials  : Breakthrough Designation (US)




# Major R&D Pipeline: Alpha

As of Jul 2021

Phase 1		Phase 2		Phase 3		Submitted	
<b>DS-7300</b> (JP/US) B7-H3-directed ADC Solid tumors	<b>DS-3201</b> (JP/US) EZH1/2 inhibitor Non-Hodgkin's lymphomas	<b>DS-3201</b> (JP) EZH1/2 inhibitor ATL/L		<b>Quizartinib</b> (JP/US/EU/Asia) FLT3 inhibitor 1L AML		<b>Mirogabaline</b> (JP) $\alpha\delta$ Ligands Central neuropathic pain	
<b>DS-6157</b> (JP/US) GPR20-directed ADC GIST	<b>PLX2853</b> (US) BET inhibitor AML	<b>DS-3201</b> (JP/US/EU/Asia) EZH1/2 inhibitor PTCL		<b>Pexidartinib</b> (JP/Asia) CSF-1/KIT/FLT3 inhibitor Tenosynovial giant cell tumor		<b>Edoxaban</b> (JP) FXa inhibitor AF in the very elderly	
<b>DS-6000</b> (US) CDH6-directed ADC Renal cell carcinoma, ovarian cancer	<b>PLX2853</b> (US) BET inhibitor Solid tumor	<b>DS-1001</b> (JP) Mutant IDH1 inhibitor Glioma		<b>Esaxerenone</b> (JP) MR blocker Diabetic nephropathy		<b>Prasugrel</b> (JP) ADP receptor inhibitor Ischemic stroke	
<b>DS-1055</b> (JP/US) Anti-GARP antibody Solid tumors	<b>PLX2853</b> (US) BET inhibitor Gynecologic neoplasms, ovarian cancer	<b>DS-5141</b> (JP) ENA oligonucleotide DMD		<b>VN-0102/JVC-001</b> (JP) Measles mumps rubella combined vaccine		<b>VN-0107/MEDI3250</b> (JP) Live attenuated influenza vaccine nasal spray	
<b>DS-1211</b> (US) TNAP inhibitor Pseudoxanthoma elasticum	<b>PLX2853</b> (US) BET inhibitor Prostate cancer						
<b>DS-6016</b> (JP) Anti-ALK2 antibody Fibrodysplasia Ossificans Progressiva	<b>DS-1594</b> (US) Menin-MLL binding inhibitor AML, ALL						
<b>DS-5670</b> (JP) mRNA vaccine COVID-19	<b>VN-0200</b> (JP) RS virus vaccine RS virus						

-  Oncology
-  Specialty medicine
-  Vaccine

AF: atrial fibrillation, ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, DMD: Duchenne muscular dystrophy, GIST: gastrointestinal stromal tumor, PTCL: peripheral T-cell lymphoma

: project in oncology that is planned to be submitted for approval based on the results of phase 2 trials : SAKIGAKE Designation (JP) : Orphan drug designation (JP/US/Europe)